#DIHYDROFOLATE
🚀 Our new paper by Shun Ito and Tomoki Miyazaki is out in ACS Chemical Biology! We developed TMP-based fluorescent probes for wash-free eDHFR imaging through systematic evaluation of different linkers and fluorophores.
pubs.acs.org/acbcct/artic...
Linker Optimization Enhances Wash-Free Imaging of Escherichia coli Dihydrofolate Reductase-Tagged Proteins
AbstractProtein tagging based on the trimethoprim (TMP)–Escherichia coli dihydrofolate reductase (eDHFR) pair enables selective fluorescence imaging throug
pubs.acs.org
November 19, 2026 at 12:13 AM
Dihydrofolate reductase supports DNA synthesis. Ligand binding makes its relaxation faster at 1–2 ps and slower at tens of ps, linking binding to motions relevant to catalysis.
Article: www.tandfonline.com/doi/full/10....
Audio: open.spotify.com/episode/4nKz...
November 18, 2026 at 1:42 PM
Glad to share our recent study on the characterization of Nocardia asteroides dihydrofolate reductase (DHFR), now published as a pre-proof in Biochimie hosted by @sfbbm.bsky.social

www.sciencedirect.com/science/arti...
Biochemical, structural, and functional characterization of the Nocardia asteroides dihydrofolate reductase: a primary target of anti-nocardiosis treatment
Nocardiosis is a human infectious disease caused by several species of Nocardia and primarily affecting the skin, lungs and central nervous system. Th…
www.sciencedirect.com
October 5, 2026 at 5:03 PM
Mtb study of 6547 genomes found 29 dfrA SNPs, 8 upstream mutations. Gln28→Leu ↑8x PAS resistance; G70T ↑13x promoter activity & PAS resistance. Mutations drive PAS resistance. 🦠💊
Mutations in dfrA and its upstream region are associated with para-aminosalicylic acid resistance in Mycobacterium tuberculosis
AbstractObjectivespara-Aminosalicylic acid is an antifolate prodrug activated in the folate biosynthesis pathway of Mycobacterium tuberculosis (Mtb), ultimately inhibiting dihydrofolate reductase encoded by dfrA. Mutations in dfrA coding and upstream regions have not been thoroughly investigated. This study aimed to assess mutations in dfrA and its upstream regulatory region in clinical Mtb isolates.MethodsWe retrieved and analysed 6547 whole-genome sequences of Mtb clinical isolates. We identified 29 SNPs in the dfrA coding region and eight mutations in the thyA–dfrA upstream region. The most prevalent coding mutations and upstream mutations were selected for functional evaluation using thermal stability analysis, GFP reporter assays and para-aminosalicylic acid drug susceptibility test (DST).ResultsThe coding mutations Trp142→Gly, Gln28→Leu and Arg32→Pro were analysed for protein thermal stability and para-aminosalicylic acid susceptibility. Gln28→Leu showed increased thermal stability relative to the WT, whereas Trp142→Gly and Arg32→Pro exhibited reduced stability. Consistently, para-aminosalicylic acid DST demonstrated that Gln28→Leu conferred an 8-fold increase in para-aminosalicylic acid resistance, while Trp142→Gly and Arg32→Pro remained phenotypically susceptible. Moreover, GFP reporter assays revealed that G70T, G59T and C48A increased promoter activity by 13-fold, 4-fold and 3-fold, respectively, whereas the remaining mutations showed no significant effect. Findings were verified by para-aminosalicylic acid DST, where G70T, G59T and C48A showed para-aminosalicylic acid resistance compared with WT.ConclusionsBy integrating genomic analysis with functional assays of thermal stability, promoter activity and drug susceptibility, this study demonstrated that mutations in dfrA coding and upstream regulatory regions contribute to para-aminosalicylic acid resistance in Mtb clinical isolates.
academic.oup.com
September 30, 2026 at 12:00 PM
🌱 The One-Carbon Master: Mastering Vitamin B9 (Folate)! 🌱
#USMLEf="/hashtag/USMLEStep1" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#USMLEStep1 #MedEd #MedicalStudent #Biochemistry #VitaminB9 #Folate #Step1Prep #HighYield #MedSchool #Hematology #OBGYN #Anemia #USMLE #FutureDoctor
Folate is the essential engine behind DNA and RNA synthesis, making it one of the most clin
U01.01.080 Vitamin B9
Test your knowledge of U01.01.080 Vitamin B9. Practice identifying the role of Dihydrofolate Reductase, the impact of drugs like Methotrexate and Phenytoin, and the classic laboratory findings of megaloblastic anemia.
mymedschool.org
April 1, 2026 at 3:03 PM
Product Description
Methotrexate Tablets (CAS 59-05-2) are high-purity, factory-manufactured anti-metabolite compounds widely used for preclinical research in oncology, autoimmune disease, and cellular biology. #highpuritychemical
arizona-mall.com/product/meth...
Methotrexate Tablets – Factory Manufactured, Low Price Wholesale | Buy Online
Methotrexate is a well-established antifolate chemotherapeutic and immunosuppressant, inhibiting nucleotide synthesis by targeting dihydrofolate reductase and other folate-dependent enzymes. Supplied as 2.5mg film-coated tablets (24 per box), manufactured by Jiangsu Zhiyuan Pharmaceutical Co., Ltd. (NMPA No.H20223032; Code 86981475000040; Barcode 6909401329106). For laboratory research only Please consult the staff for other purposes.
arizona-mall.com
November 19, 2025 at 6:29 PM
Methotrexate Tablets – 2.5 mg Wholesale price comparison

Methotrexate is a well-established antifolate chemotherapeutic and immunosuppressant, inhibiting nucleotide synthesis by targeting dihydrofolate reductase and other folate-dependent enzymes. Supplied as 2.5 mg film-coated tablets (24 per…
Methotrexate Tablets – 2.5 mg Wholesale price comparison
Methotrexate is a well-established antifolate chemotherapeutic and immunosuppressant, inhibiting nucleotide synthesis by targeting dihydrofolate reductase and other folate-dependent enzymes. Supplied as 2.5 mg film-coated tablets (24 per box), manufactured by Jiangsu Zhiyuan Pharmaceutical Co., Ltd. (NMPA No. H20223032; Code 86981475000040; Barcode 6909401329106). For laboratory research only
arizona-mall.com
June 20, 2025 at 6:23 AM
One of the enzymes inhibited by cotrimoxazole (dihydrofolate reductase) even exists in mammals. However, apparently it is not inhibited very well by trimethoprim (part of cotrimoxazole).
July 12, 2026 at 12:08 PM
Pathogens, Vol. 15, Pages 233: Persistent and Circulating Plasmodium falciparum dhfr and dhps Mutations in Busia County, Western Kenya Pathogens
Pathogens, Vol. 15, Pages 233: Persistent and Circulating Plasmodium falciparum dhfr and dhps Mutations in Busia County, Western Kenya
Malaria in pregnancy remains a major driver of poor maternal and neonatal health outcomes in sub-Saharan Africa. For decades, intermittent preventive treatment in pregnancy (IPTp), with sulphadoxine-pyrimethamine (SP), has mitigated malaria-associated health risks, but concerns have been raised regarding accumulated Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutations on the efficacy of SP. Western Kenya, including Busia County, is a high malaria transmission setting where molecular surveillance of dhfr and dhps mutations remains limited. This study assessed the prevalence and haplotype structure of dhfr and dhps mutations in P. falciparum isolates from Busia County, Kenya. A total of 66 samples of P. falciparum isolates collected from patients attending Matayos Sub-County Hospital between November 2024 and January 2025 were analysed. PCR amplification and Sanger sequencing targeted dhfr codons C50R, N51I, C59R, S108N/T, I164L, and dhps codons I431V, S436A/F, A437G, K540E, A581G, and A613S/T to determine mutation frequencies, haplotypes, and combined dhps and dhfr haplotype profiles. High frequencies of dhfr and dhps mutations were observed across the parasite isolates. The most common dhfr substitutions included N51I (85.2%) and C59R (75.4%), while S108N (32.8%) and S108T (19.7%) were detected at lower frequencies. Dhfr haplotypes identified included N51I + C59R, N51I + C59R + S108N, and a N51I + C59R + S108T + I164L variant. The I164L mutation was detected at a frequency of 18.0% and was observed exclusively on a non-canonical S108T background (19.7%). Dhps haplotypes were dominated by A437G (92.3%), K540E (40%) alone, and the A437G + K540E double mutant. Combined dhfr and dhps haplotype analyses revealed circulation of classical dhfr triple-mutant (N51I + C59R + S108N) backgrounds with dhps A437G. Quintuple haplotypes (dhfr N51I + C59R + S108T + I164L with dhps A437G) and rare complex haplotypes incorporating both I164L and K540E or I164L and S436F were also detected. These findings indicate the persistence and circulation of both canonical and non-canonical dhfr and dhps haplotypes in P. falciparum isolates from Busia County. This study highlights the need for continuous molecular and phenotypic surveillance to clarify the functional and epidemiological significance of parasites carrying S108T and I164L mutations, and to inform IPT policy.
dlvr.it
February 21, 2026 at 5:18 PM
Pathogens, Vol. 15, Pages 233: Persistent and Circulating Plasmodium falciparum dhfr and dhps Mutations in Busia County, Western Kenya Pathogens
Pathogens, Vol. 15, Pages 233: Persistent and Circulating Plasmodium falciparum dhfr and dhps Mutations in Busia County, Western Kenya
Malaria in pregnancy remains a major driver of poor maternal and neonatal health outcomes in sub-Saharan Africa. For decades, intermittent preventive treatment in pregnancy (IPTp), with sulphadoxine-pyrimethamine (SP), has mitigated malaria-associated health risks, but concerns have been raised regarding accumulated Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutations on the efficacy of SP. Western Kenya, including Busia County, is a high malaria transmission setting where molecular surveillance of dhfr and dhps mutations remains limited. This study assessed the prevalence and haplotype structure of dhfr and dhps mutations in P. falciparum isolates from Busia County, Kenya. A total of 66 samples of P. falciparum isolates collected from patients attending Matayos Sub-County Hospital between November 2024 and January 2025 were analysed. PCR amplification and Sanger sequencing targeted dhfr codons C50R, N51I, C59R, S108N/T, I164L, and dhps codons I431V, S436A/F, A437G, K540E, A581G, and A613S/T to determine mutation frequencies, haplotypes, and combined dhps and dhfr haplotype profiles. High frequencies of dhfr and dhps mutations were observed across the parasite isolates. The most common dhfr substitutions included N51I (85.2%) and C59R (75.4%), while S108N (32.8%) and S108T (19.7%) were detected at lower frequencies. Dhfr haplotypes identified included N51I + C59R, N51I + C59R + S108N, and a N51I + C59R + S108T + I164L variant. The I164L mutation was detected at a frequency of 18.0% and was observed exclusively on a non-canonical S108T background (19.7%). Dhps haplotypes were dominated by A437G (92.3%), K540E (40%) alone, and the A437G + K540E double mutant. Combined dhfr and dhps haplotype analyses revealed circulation of classical dhfr triple-mutant (N51I + C59R + S108N) backgrounds with dhps A437G. Quintuple haplotypes (dhfr N51I + C59R + S108T + I164L with dhps A437G) and rare complex haplotypes incorporating both I164L and K540E or I164L and S436F were also detected. These findings indicate the persistence and circulation of both canonical and non-canonical dhfr and dhps haplotypes in P. falciparum isolates from Busia County. This study highlights the need for continuous molecular and phenotypic surveillance to clarify the functional and epidemiological significance of parasites carrying S108T and I164L mutations, and to inform IPT policy.
dlvr.it
February 20, 2026 at 10:17 AM
Adaptive Landscapes of Plasmodium Falciparum Dihydrofolate Reductase Reveal Pathways to Antifolate Resistance bioRxivpreprint
Adaptive Landscapes of Plasmodium Falciparum Dihydrofolate Reductase Reveal Pathways to Antifolate Resistance
Antifolate resistance in P. falciparum dihydrofolate reductase remains a major challenge for malaria control. To understand how this enzyme preserves function under antifolate selection, we developed PfPATH, a computational framework that integrates mutational fitness measurements, evolutionary interactions, and structural information to map plausible adaptive trajectories. PfPATH adaptive walks reveal that only a small subset of residues forms a constrained adaptive ridge that guides evolution. Most resistance mutations are harmful on their own and only become viable when supported by stabilizing changes. Hence, adaptation is confined to a few constrained pathways yielding high resistance. Structural network analyses indicate that these resistance mutations do not disrupt the overall enzyme architecture. Instead, they reorganize internal communication in a way that preserves catalytic function. We further showed through molecular dynamics and free-energy analyses that resistant variants remain structurally stable while exploring broader low-energy conformational substates. In conclusion, our work reveals a narrow and predictable route to antifolate escape, with implications for anticipating resistance evolution and guiding future drug design.
dlvr.it
January 9, 2026 at 4:55 AM
Adaptive Landscapes of Plasmodium Falciparum Dihydrofolate Reductase Reveal Pathways to Antifolate Resistance bioRxivpreprint
Adaptive Landscapes of Plasmodium Falciparum Dihydrofolate Reductase Reveal Pathways to Antifolate Resistance
Antifolate resistance in P. falciparum dihydrofolate reductase remains a major challenge for malaria control. To understand how this enzyme preserves function under antifolate selection, we developed PfPATH, a computational framework that integrates mutational fitness measurements, evolutionary interactions, and structural information to map plausible adaptive trajectories. PfPATH adaptive walks reveal that only a small subset of residues forms a constrained adaptive ridge that guides evolution. Most resistance mutations are harmful on their own and only become viable when supported by stabilizing changes. Hence, adaptation is confined to a few constrained pathways yielding high resistance. Structural network analyses indicate that these resistance mutations do not disrupt the overall enzyme architecture. Instead, they reorganize internal communication in a way that preserves catalytic function. We further showed through molecular dynamics and free-energy analyses that resistant variants remain structurally stable while exploring broader low-energy conformational substates. In conclusion, our work reveals a narrow and predictable route to antifolate escape, with implications for anticipating resistance evolution and guiding future drug design.
dlvr.it
January 7, 2026 at 9:54 PM
Convenient screening for drug resistance mutations from historical febrile malaria samples across Kenya bioRxivpreprint
Convenient screening for drug resistance mutations from historical febrile malaria samples across Kenya
Background Historically, chloroquine resistance emerged that was driven by mutations in the chloroquine resistance transporter (Pfcrt) gene. This led to the global withdrawal of chloroquine in 1998 and its subsequent replacement with sulfadoxine-pyrimethamine, whose efficacy was compromised by a high prevalence of mutations in the dihydrofolate reductase and the dihydropteroate synthase genes by 2004. Consequently, artemisinin-based combination therapies (ACTs) were introduced in 2006. Since then, thirteen mutations in the kelch 13 (Pfk13) propeller domain have emerged and validated by the World Health Organization (WHO) as markers of partial artemisinin resistance. This study aimed to characterize temporal trends in both established, Pfcrt and Pfk13 and less well-described potential markers, cysteine desulfurase (Pfnfs) and Pfcoronin, using febrile malaria samples collected across diverse regions of Kenya between 2013 and 2022. Methods The temporal trend of these markers of resistance were assessed by screening archived P. falciparum positive dried blood spots (DBS). A total of 1,750 DBS samples collected from Therapeutic Efficacy Studies (TES) conducted in: Kwale (2013, n=350), Kisumu (2015, n=314), Busia (2016, n=334), Kisii (2017, n=314), Kwale (2018, n=150), and a hrp2 study conducted Kisii (2022, n=288). Parasite genomic DNA was extracted using the Chelex-saponin method and confirmed by a Pf 18S RT-PCR. Pfk13, Pfcrt, Pfnfs and Pfcoronin PCR amplicons were sequenced using capillary electrophoresis, Illumina Miseq or the Oxford Nanopore (GridION) platform. Results The prevalence of Pfcrt mutations declined over time and no WHO validated Pfk13 mutations associated with artemisinin resistance were detected. However, synonymous substitutions at WHO-validated codons C469C and P553P were identified. In the PfCoronin gene, non-synonymous mutations distinct from those reported in West Africa were observed at high frequencies (>75%). Notably, the Pfnfs-K65Q mutation, previously associated with reduced lumefantrine sensitivity in West Africa, was detected in over 80% of samples. Our findings reveal differences in some antimalarial resistance genetic markers between observations made in The Gambia and Senegal (West Africa) and Kilifi (East Africa). Based on the convenient sample set, there were no WHO validated k13 mutations up until 2022, suggesting continued ACT efficacy in Kenya. This study underscores the importance of continued molecular surveillance and suggests that resistance may evolve through different pathways in East compared to West Africa and Southeast Asia.
dlvr.it
September 17, 2025 at 11:46 AM
Convenient screening for drug resistance mutations from historical febrile malaria samples across Kenya bioRxivpreprint
Convenient screening for drug resistance mutations from historical febrile malaria samples across Kenya
Background Historically, chloroquine resistance emerged that was driven by mutations in the chloroquine resistance transporter (Pfcrt) gene. This led to the global withdrawal of chloroquine in 1998 and its subsequent replacement with sulfadoxine-pyrimethamine, whose efficacy was compromised by a high prevalence of mutations in the dihydrofolate reductase and the dihydropteroate synthase genes by 2004. Consequently, artemisinin-based combination therapies (ACTs) were introduced in 2006. Since then, thirteen mutations in the kelch 13 (Pfk13) propeller domain have emerged and validated by the World Health Organization (WHO) as markers of partial artemisinin resistance. This study aimed to characterize temporal trends in both established, Pfcrt and Pfk13 and less well-described potential markers, cysteine desulfurase (Pfnfs) and Pfcoronin, using febrile malaria samples collected across diverse regions of Kenya between 2013 and 2022. Methods The temporal trend of these markers of resistance were assessed by screening archived P. falciparum positive dried blood spots (DBS). A total of 1,750 DBS samples collected from Therapeutic Efficacy Studies (TES) conducted in: Kwale (2013, n=350), Kisumu (2015, n=314), Busia (2016, n=334), Kisii (2017, n=314), Kwale (2018, n=150), and a hrp2 study conducted Kisii (2022, n=288). Parasite genomic DNA was extracted using the Chelex-saponin method and confirmed by a Pf 18S RT-PCR. Pfk13, Pfcrt, Pfnfs and Pfcoronin PCR amplicons were sequenced using capillary electrophoresis, Illumina Miseq or the Oxford Nanopore (GridION) platform. Results The prevalence of Pfcrt mutations declined over time and no WHO validated Pfk13 mutations associated with artemisinin resistance were detected. However, synonymous substitutions at WHO-validated codons C469C and P553P were identified. In the PfCoronin gene, non-synonymous mutations distinct from those reported in West Africa were observed at high frequencies (>75%). Notably, the Pfnfs-K65Q mutation, previously associated with reduced lumefantrine sensitivity in West Africa, was detected in over 80% of samples. Our findings reveal differences in some antimalarial resistance genetic markers between observations made in The Gambia and Senegal (West Africa) and Kilifi (East Africa). Based on the convenient sample set, there were no WHO validated k13 mutations up until 2022, suggesting continued ACT efficacy in Kenya. This study underscores the importance of continued molecular surveillance and suggests that resistance may evolve through different pathways in East compared to West Africa and Southeast Asia.
dlvr.it
September 16, 2025 at 4:45 AM
New preprint is out! Proud to have contributed to this work in which we detail how light-modulated allostery influences catalysis and protein function in our designed enzymatic photoswitch with James McCormick, @jerrydinan.bsky.social, and @kreynoldslab.bsky.social 🧪🧬🦠
Local disorder is associated with enhanced catalysis in an engineered photoswitch
The A. sativa LOV2 domain is commonly harnessed as a source of light-based regulation in engineered optogenetic switches. In prior work, we used LOV2 to create a light-regulated Dihydrofolate Reductas...
www.biorxiv.org
November 30, 2024 at 10:11 PM
There is a lot more discussed in the preprint, but I’ll wrap up with some thoughts about the future. 10/n
www.biorxiv.org/content/10.1...
Exploring Antibiotic Resistance in Diverse Homologs of the Dihydrofolate Reductase Protein Family through Broad Mutational Scanning
Current antibiotic resistance studies often focus on individual protein variants, neglecting broader protein family dynamics. Dihydrofolate reductase (DHFR), a key antibiotic target, has been extensiv...
www.biorxiv.org
January 28, 2025 at 1:42 AM
@claudele.bsky.social et al. studied the fundamental question of how enzymatic activity emerges by focusing on type B dihydrofolate reductases, suggesting DfrB domains evolved rudimentary catalysis from a binding capacity.

🔗 doi.org/10.1093/molbev/msaf215

#evobio #molbio
From Binding to Catalysis: Emergence of a Rudimentary Enzyme Conferring Intrinsic Antibiotic Resistance
Abstract. How does enzymatic activity emerge? To shed light on this fundamental question, we study type B dihydrofolate reductases (DfrB), which were disco
doi.org
October 3, 2025 at 11:37 AM
The authors included RRIDs in their in Journal of Molecular Structure paper! We value the author's support of reproducibility. #BetterScience #reproducibility #methodsmatter
Pyrazole-linked quinoline hydrazone derivatives: Design, synthesis, antimicrobial and antiproliferative activity via dihydrofolate reductase inhibition
Read the full paper: Pyrazole-linked quinoline hydrazone derivatives: Design, synthesis, antimicrobial and antiproliferative activity via dihydrofolate reductase inhibition
doi.org
July 2, 2026 at 7:00 AM
RRIDs were included in this in Molecular Imaging and Biology paper. We value the author's support of reproducibility. #methodsmatter #reproducibility #STMpublishing
First-in-Human Biodistribution and Dosimetry of [11C]Trimethoprim - Molecular Imaging and Biology
Abstract Trimethoprim (TMP) is a reversible inhibitor of the prokaryotic enzyme dihydrofolate reductase (DHFR) used for the treatment or prophylaxis of bacterial infections. [11C]trimethoprim ([11C]TMP) is a positron emission tomography (PET) imaging isotopologue of TMP. TMP binds with 30,000-fold greater affinity to bacterial DHFR over the homologous mammalian enzyme in vitro, suggesting [11C]TMP may selectively accumulate in tissues with cells expressing bacterial DHFR. This study characterizes the biodistribution and dosimetry of [11C]TMP, informing its use in imaging bacterial infections and tracking mammalian cells expressing eDHFR as a reporter gene. Methods Four males with suspected infection, aged 59 ± 10 years old (mean ± SD) received 3 serial PET/CT scans after injection of 346 ± 305 MBq (range 129–797 MBq) of [11C]TMP. Organ activities were measured in MIM v6.7, including brain, kidneys, spleen, liver, heart, lungs, bl
doi.org
March 12, 2026 at 7:00 AM
A paper using RRID:Addgene_46819 was just published in International Journal of Molecular Sciences see "Development of a Dihydrofolate Reductase Selection System for Saccharomyces boulardii". RRIDs like this improve reproducibility in scientific research. #methodsmatter #RRID
doi.org
April 5, 2025 at 7:01 AM
A paper using RRID:Addgene_134817 was just published in Rxiv see "Exploring Antibiotic Resistance in Diverse Homologs of the Dihydrofolate Reductase Protein Family through Broad Mutational Scanning". Thank you for making your methods matter! #OpenScience #STMpublishing
doi.org
March 30, 2025 at 7:01 AM
RRID:Addgene_63670, was just reported to be used in "DHFR2 RNA directly regulates dihydrofolate reductase and its expression level impacts folate one carbon metabolism". RRIDs like this improve reproducibility in scientific research. #STMpublishing #methodsmatter
doi.org
March 27, 2025 at 10:13 PM